Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
Conditions
Interventions
Intervention1: Azithromycin tab and topical clindamycin: Tab Azithromycin 500mg OD 3 times a week for 8 weeks and topical Clindamycin 1% every night for 8 weeks
Control Intervention1: Tab Doxycycline
Sponsors
Dr Apoorva
Eligibility
Inclusion criteria
Inclusion criteria: Willingness to give written informed consent and availability for regular followup. Subjects with Acne Vulgaris of grade 2 and 3 as per the investigators global assessment scale. Subjects must be willing to refrain from using all other topical Acne medications or antibiotics during the 8 week treatment period.
Exclusion criteria
Exclusion criteria: Subjects with severe acne, nodulocystic lesions, acne conglobate, acne fulminans, acne rosacea, secondary(drug induced) acne.ion ingestion. Subjects with a history of hypersensitivity or allergy to any study medication ingredients. Subjects who have participated in any investigational drug study within 30 days prior to baseline will be excluded from participation. Female subjects who are pregnant,lactating or planning to become pregnant during study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to compare costeffectiveness between azithromycin and doxycycline with clindamycin in treatment of patients with moderate to severe acne vulgarisTimepoint: 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life will be assessed using DLQI scoreTimepoint: 8weeks | — |
Countries
India
Contacts
Public ContactDr APOORVA
KEMPEGOWDA INSTITUTE OF MEDICAL SCIENCES,BANGALORE,affiliated under RGUHS
Outcome results
None listed